You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Twitter Demographics
Mendeley readers
Attention Score in Context
| Title |
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, September 2013
|
| DOI | 10.2147/ndt.s33949 |
| Pubmed ID | |
| Authors |
Florian Castrop, Haslinger, Bernhard Hemmer, Dorothea Buck |
| Abstract |
Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta. |
Twitter Demographics
The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Turkey | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 44 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 15% |
| Other | 7 | 15% |
| Student > Bachelor | 5 | 11% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Master | 5 | 11% |
| Other | 10 | 21% |
| Unknown | 8 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 30% |
| Agricultural and Biological Sciences | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Nursing and Health Professions | 3 | 6% |
| Immunology and Microbiology | 2 | 4% |
| Other | 8 | 17% |
| Unknown | 11 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2013.
All research outputs
#15,280,625
of 22,723,682 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,778
of 2,977 outputs
Outputs of similar age
#123,883
of 200,188 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#46
of 67 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,977 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,188 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.